NCT07456189尚未招募不适用
The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary Infiltrating
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 20
- 主要终点
- Overall Survival
研究概览
简要总结
Application of Stereotactic Body Radiotherapy (SBRT) Bridging to Allogeneic Hematopoietic Stem Cell Transplantation in Adult Hematological Malignance Patients with Extramedullary Lesions. This study aims to improve transplantation outcomes with extramedullary lesions. The investigators aim to study the Post-Transplantation Evaluation of Disease-Free Survival, Overall Survival, Treatment-Related Mortality, Cumulative Recurrence Rate, Post-Transplantation Complications, and Safety Data.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who meet all of the following criteria are eligible for enrollment in this study:
- •Age between 18 and 60 years.
- •A confirmed diagnosis of a hematologic malignancy, including but not limited to Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myeloid Leukemia (CML), Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma (NHL), Hodgkin Lymphoma (HL), and Multiple Myeloma (MM).
- •Diagnosis of extramedullary disease/lesions confirmed by one of the following: pathological biopsy, cytology, or at least one imaging modality (including PET-CT, contrast-enhanced CT, or contrast-enhanced MRI).
- •Presence of a suitable donor and scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- •Karnofsky Performance Status (KPS) score > 60% or Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to
- •Has not participated in any other clinical trial involving cell-based or immunotherapies for the treatment of the primary disease.
- •The subject voluntarily agrees to participate in the study, demonstrates good compliance, and is willing to cooperate with follow-up procedures.
- •A signed informed consent form must be obtained prior to the initiation of any study-related procedures. For subjects aged 18 years or older, consent is to be provided by the subject or their immediate family member. If, in the physician's judgment, obtaining consent directly from the subject is not in the patient's best interest regarding their medical condition, the informed consent form may be signed by the legal guardian or an immediate family member of the patient
排除标准
- •Previous history of one or more autologous or allogeneic stem cell transplants prior to enrollment.
- •Uncontrolled infection at the time of enrollment, or requirement for mechanical ventilatory assistance, or hemodynamic instability.
- •Severe organ dysfunction, including but not limited to hepatic or renal impairment, and heart failure.
- •Evidence of active HIV replication; positive HCV antibody and detectable HCV-RNA within 90 days prior to enrollment; or positive HBsAg. Known seropositivity for HIV or active hepatitis C virus.
- •Presence of psychiatric disorders or any other condition that, in the investigator's opinion, would compromise the subject's ability to cooperate with study treatment and monitoring requirements.
- •Inability or unwillingness to provide written informed consent.
- •Any other condition or circumstance that, in the judgment of the investigator, may pose a risk to the subject or prevent the subject from meeting or fulfilling the study requirements.
研究组 & 干预措施
SBRT+HSCT
Experimental
participants in this arm recieve the treatment of SBRT before bridging to HSCT
干预措施: Stereotactic body radiotherapy (SBRT) (Radiation)
结局指标
主要结局
Overall Survival
时间窗: one year
次要结局
- relapse free survival(one year)
- cumulative incidence of relapse(one year)
- treatment related mortality(one year)
- Extramedullary disease evaluation (RECIST v1.1)(one year)
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)(one year)
研究者
相似试验
已完成
不适用
Stereotactic Radiotherapy Treatment for Treatment-Resistant DepressionNCT07274917Capital Medical University9
招募中
不适用
Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung LesionsNCT07401615Istituto Clinico Humanitas150
招募中
不适用
Adaptive Stereotactic Radiotherapy for Localized Prostate CancerNCT07344844Clinique Sainte Clotilde100
撤回
2 期
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder CancerNCT07414992Memorial Sloan Kettering Cancer Center44
招募中
不适用
SBRT Technique Implementation for Spinal Metastases IrradiationNCT07429422Institute of Oncology Ljubljana100